Second, the 2-year follow-up period for longitudinal analysis also might not be sufficient to confirm some relationship between AD biomarkers and WMHs; for example, the relationship of baseline WMH volume with the change of brain Aβ or tau over 2 years. Here, MAPT is linked to Alzheimer disease.